戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ideline-recommended medications (aspirin and beta-adrenergic blocking agents).
2 t with either alpha-2 adrenergic agonists or beta adrenergic blocking agents.
3 treating chronic heart failure patients with beta-adrenergic blocking agents.
4 ats/min, p < 0.0001) and more often received beta-adrenergic blocking agents (49% vs. 14%, p < 0.0001
5       However, for the subset of patients on beta-adrenergic blocking agents after CABG, there was a
6 ed long-term health outcomes associated with beta-adrenergic blocking agents and diltiazem treatment
7 omen; mean age 57 years) who were not taking beta-adrenergic blocking agents and were referred for sy
8 inical Question: Does nurse-led titration of beta-adrenergic blocking agents, angiotensin-converting
9                          The use of aspirin, beta-adrenergic blocking agents, angiotensin-converting
10 pitals with such capability when aspirin and beta-adrenergic blocking agents are given appropriately
11                                              Beta-adrenergic blocking agents are used in most patient
12 al treatments for patients with AMI, such as beta-adrenergic blocking agents, aspirin and immediate r
13 sease or the use of concomitant medications (beta-adrenergic blocking agents, calcium channel blockin
14 lysis of several studies with the alpha- and beta-adrenergic blocking agent carvedilol demonstrated a
15 n include initial therapy with a diuretic or beta-adrenergic blocking agent, for which reductions in
16                       Chronic treatment with beta-adrenergic blocking agents has been shown to improv
17                                              Beta-adrenergic blocking agents have been revalidated in
18 ey were also more likely to receive aspirin, beta-adrenergic blocking agents, heparin and nitrates (a
19 ven medications such as aspirin, statins and beta-adrenergic blocking agents in conjunction with comp
20 sure in cardiomyopathy patients treated with beta-adrenergic blocking agents is controversial.
21 udy was designed to examine the effects of a beta-adrenergic blocking agent on the ischemic response
22 ensin-converting enzyme (ACE) inhibitors and beta-adrenergic blocking agents on the remodeling proces
23 ents with stable angina pectoris receiving a beta-adrenergic blocking agent or calcium antagonist, or
24 treatment with either timolol, a nonspecific beta adrenergic blocking agent, or with para-aminoclonid
25 lations: patients with first MI, patients on beta-adrenergic blocking agents, patients with LVEF < or
26 ver, group 1 patients had significantly less beta-adrenergic blocking agent use and higher ejection f
27 his analysis was performed to assess whether beta-adrenergic blocking agent use is associated with re
28 ox multivariate analysis, the association of beta-adrenergic blocking agent use with reduced mortalit
29 atients; After adjusting for age, gender and beta-adrenergic blocking agent use, multiple logistic re
30 inversely to prior myocardial infarction and beta-adrenergic blocking agent use.
31                                              Beta-adrenergic blocking agents were administered concur
32 Angiotensin-converting-enzyme inhibitors and beta-adrenergic-blocking agents were administered if the
33                                   Sotalol, a beta-adrenergic blocking agent with class III antiarrhyt

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。